Showing results (231-240 of 258) with videos related to

Sort By:
Pageof 26
NEJM Evidence|February 6, 2024
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia VeraTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
British Journal of Haematology|November 13, 2024
Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndromeCarmelo Gurnari, Elisa Galossi, Eleonora Lumia, et al.
Annals of Hematology|December 7, 2023
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomesTiziano Barbui, Alessandra Carobbio, Valerio De Stefano, et al.
British Journal of Haematology|November 22, 2020
Second primary malignancy in myelofibrosis patients treated with ruxolitinibNicola Polverelli, Elena M Elli, Elisabetta Abruzzese, et al.
Cancer|March 18, 2023
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcomeFrancesca Palandri, Massimo Breccia, Camilla Mazzoni, et al.
Haematologica|March 2, 2019
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practiceCarmen Fava, Giovanna Rege-Cambrin, Irene Dogliotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2017
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating AgentsSophie Park, Jean-François Hamel, Andrea Toma, et al.
Bone Marrow Transplantation|February 24, 2025
Tuberculosis after hematopoietic cell transplantation: retrospective study on behalf of the Infectious Diseases Working Party of the EBMTJoanna Drozd-Sokołowska, Gloria Tridello, Inge Verheggen, et al.
Pageof 26